

EQA round: BIL2/23 - Bilirubin Neonatal

Deadline: 25.8.2023

Setup: groups - measurement principle; minimal size of the groups n = 5

RoM = robust average

SD = standard deviation

CV = coefficient of variation

N_{tot} = total number of the resultsN_{out} = number of the results removed before calculation

AV = assigned value

CVP = consensus of all participants

U_{AV} = expanded uncertainty of the assigned value (k = 2)D_{max} = acceptable difference

LL = lower limit

UL = upper limit

N_{eva} = number of the results assessedN_{suc} = number of successful resultsS_{rel} = relative success

Test Sample Group	[unit]	RoM	SD	CV [%]	N _{tot}	N _{out}	Comparability					N _{eva}	N _{suc}	S _{rel} [%]	
							AV	U _{AV}	D _{max}	LL	UL				
(215) Bilirubin total	[μmol/L]				120							120	115	96	
Sample A		319	20	6,3	120		CVP	319	4,5	18%	261	377	120	115	96
(1) Jendrassik - Gróf		324	15	4,5	10	0							10		
(2) DCA, DPD		313	15	4,8	91	0							91		
(7) Oxidation-reduction methods		349	30	8,6	15	0							15		
Other					4	0							4		
							3x 3, 1x 5								
Sample B		208	14	6,8	120		CVP	208	3,1	18%	170	246	120	118	98
(1) Jendrassik - Gróf		209	10	4,9	10	0							10		
(2) DCA, DPD		204	10	5,1	91	0							91		
(7) Oxidation-reduction methods		230	14	5,9	15	0							15		
Other					4	0							4		
							3x 3, 1x 5								